I just saw that this press release from Elysium was posted on their website yesterday. Unfortunately, it could be several months before they release details of blood pressure, serum glucose levels, cholesterol levels, weight change, 6 mile walk endurance test, sleep patterns, etc in a peer reviewed scientific journal as they say they will:
Elysium also announced today that its first human clinical trial designed to evaluate the safety and efficacy of its first product, BASIS™, met its primary and secondary endpoints. The study, which was placebo-controlled, randomized, and double-blinded, evaluated the safety and efficacy of BASIS™ [nicotinamide riboside (NR) and pterostilbene] in 120 healthy participants ages 60-80 over an eight-week period. Participants received either the recommended dose (250 mg NR and 50 mg pterostilbene), double the recommended dose or a placebo daily for the eight-week trial.
The study found that participants experienced no serious adverse events and confirmed that BASIS™ is safe for daily use as determined by standard safety measures.The study also showed that in participants taking the recommended dose of BASIS, ™ NAD+ levels increased from baseline in whole blood by an average of 40% at four weeks and maintained that increase for the duration of the trial. Participants taking double the recommended daily dose saw their NAD+ levels increase approximately 90% at four weeks, and a significantly higher level of NAD+ (compared to the recommended dose of BASIS™) was maintained for the duration of the trial. This first-in-humans study demonstrates clearly that BASIS™ can increase NAD+ levels in the blood safely and sustainably. Confirming that BASIS™ is an effective NAD+ precursor in humans is a vital first step to elucidating how BASIS™ supports human health.
“As we age, NAD+ levels in our cells decline. The trial results, which are the first of their kind, indicate that BASIS™ increases NAD+ levels in a sustained way. And since NAD+ is involved in hundreds of critical cellular processes, it is a vitally important component to optimizing our cellular health as we get older,” said Dr. Lenny Guarente, chief scientific officer and co-founder of Elysium who also serves as the director of the Glenn Laboratory for the Science of Aging at Massachusetts Institute of Technology. “We plan to submit the full results of the trial to a peer-reviewed scientific journal.”